Human Genome Sciences — JP Morgan Healthcare Conference 2012
29 slides from Human Genome Sciences's conference presentation, Jan 9, 2012
Slide 1: Benlysta and Beyond
Benlysta(r) And beyond H. Thomas Watkins President and Chief Executive Officer JP Morgan Healthcare Conference January 9, 2012
Slide 2: Note Regarding Forward-Looking Statements
2 Note Regarding Forward-Looking Statements This presentation includes statements that are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include those regarding our expectations for BENLYSTA(r), business goals for 2012, a
Slide 3: Near-Term: Redefining SLE Treatment
NEAR-TERM: REDEFINING SLE TREATMENT BENLYSTA(r): first drug approved for SLE in more than 50 years Launched in U.S. late March 20111 Launched Germany and Canada (Q3), Spain and other European countries 2H11 Initial U.S. market-est. 200,000 SLE patients appropriate for BENLYSTA1,2 Specialty sales for
Slide 4: Long-Term: Expanding on Benlysta and Other Opportunities
Long-term: expanding on benlysta and other opportunities BENLYSTA: expand market opportunity Initiated Phase 3 subcutaneous formulation trial Dec. 2011 Expect to initiate Phase 3 vasculitis trial 2H 2012 Expect to initiate Phase 3 lupus nephritis trial 2H 2012 Proof of concept/exploratory studies in
Slide 5: Benlysta: Redefining SLE Treatment
Benlysta REDEFINING SLE TREATMENT
Slide 6: Initial Target: 200,000 Patients
Moderate 45% Severe 22% Initial Target: 200,000 Patients Over the Course of Their Disease2,3 Estimated 1,500,000 Patients with Lupus and Related Conditions1 325,000 SLE Patients Treated by Rheumatologists2 BENLYSTA INITIAL U.S. Market estimate: 200,000 Patients2,3 6 1 Per Lupus Foundation of America
Slide 7: Benlysta Positioning in SLE Treatment Algorithm
Benlysta positioning in SLE treatment algorithm1 Initial Therapy Anti-malarials Low dose corticosteroids Acute (severe active)1 Intensified Therapy (persistent symptoms) 7 Chronic High dose corticosteroids Immunosuppressants Methotrexate Mycophenolate mofetil Azathioprine 5% Acute (severe active)1 C
Slide 8: 2011 Benlysta U.S. Weekly Gross Sales
(CHART) 2011 BENLYSTA U.S. WEEKLY GROSS SALES 8 4-week average gross sales ($Mil.) Q2 Gross 8.6 Net 7.6 Q3 Gross 21.3 Net 18.8 Q4 (est.) Gross 29.1 Net 25.7 July 4th Thanksgiving Labor Day Memorial Day Christmas 1.7
Slide 9: Driving Paradigm Change in SLE Treatment
Patient identified/ verify benefits Education Patient Selection/ Qualification Trial Adoption DRIVING PARADIGM CHANGE IN SLE TREATMENT 9 Understand clinical data Translate data to real life practice Determine appropriate patient profiles Select individual patients Secure reimbursement Complete patie
Slide 10: Focus in 2011: Driving Account Penetration
FOCUS in 2011: Driving AcCounT Penetration Working towards changing SLE treatment paradigm with BENLYSTA Majority of rheumatologists who started BENLYSTA are in trial mode; early anecdotal feedback favorable Key indicators heading steadily in the right direction >90% of rheumatologists surveyed inte
Slide 11: Majority of Surveyed Rheumatologists Have Begun to Prescribe Benlysta
11 Q9. Have you prescribed BENLYSTA (belimumab) to any of your SLE patients? Q14. Previously, you indicated you anticipate using BENLYSTA in your SLE patients. How soon do you anticipate you would begin using BENLYSTA? Source: HGS market research Majority of Rheumatologists SURVEYED have begun to pr
Slide 12: High Volume Infusion Centers Begin to Adopt Benlysta
High volume infusion centers have begun to adopt BENLYSTA more broadly Hospital penetration follows with continued progress with formulary approvals 12 Leading indicators of broader adoption (CHART) (CHART) $3.2 $1.1 $0.2
Slide 13: Factors Influencing Broader Adoption by Physicians
Enhanced speakers program Direct to patient education Peer-to-peer education Clinical data/ publications J-Code Accumulated clinical experience Patient identified/ verify benefits Factors that influence broader adoption of benlysta by physicians 13 Increases/Decreases urgency to initiate therapy Ins
Slide 14: Benlysta Continues to Gain Greater Access
BENLYSTA continues to GAIN GREATER ACCESS Product specific J-Code effective Jan. 1, 2012 Payer reimbursement - relevant for community accounts ~70% of patients BENLYSTA covered for nearly all covered lives (50%+ by policy, remainder by exception) BENLYSTA reimbursement experience spreading Hospital
Slide 15: Significant Opportunity Outside the U.S.
BENLYSTA REpresents a significant opportunity outside the u.s.1 15 1 In the E.U., BENLYSTA is indicated as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus (SLE), with a high degree of disease activity (e.g. positive anti-dsDNA and low complement), d
Slide 16: Broad Potential Beyond Initial Market Entry in SLE
Proof-of-Concept/ Exploratory Studies Sjogren's Syndrome1 Waldenstrom's Disease1 Transplant1 Idiopathic thrombocytopenic purpura Myasthenia gravis Idiopathic membranous nephropathy Broad Potential Beyond Initial Market Entry in SLE Subcutaneous Formulation May enable weekly self-administration Initi
Slide 17: Benlysta Subcutaneous Formulation
BENLYSTA SUBCUTANEOUS FORMULATION INITIATED Q4 2011 New formulation may enable weekly self-administration Phase 3, placebo-controlled, worldwide, "BLISS-like" Approximately 816 SLE patients randomized 2:1 BENLYSTA 200 mg weekly plus std therapy vs. placebo plus std therapy Initial results anticipate
Slide 18: ANCA-Associated Vasculitis
ANCA-ASSOCIATED VASCULITIS PLANNED 2H 2012 Autoimmune condition that involves inflammation in the blood vessels Associated with elevated BLyS Unmet need for new treatment with proven efficacy and acceptable safety/tolerability BENLYSTA Phase 3 data showed clinical improvement in vasculitis domain Po
Slide 19: Active Lupus Nephritis
ACTIVE Lupus Nephritis planned 2H 2012 BLISS studies excluded patients with severe active lupus nephritis Important unmet need Study potentially label enabling Expect to initiate Phase 3 study in patients with active lupus nephritis 2H 2012 19
Slide 20: Broad Potential in a Pipeline of Underserved Markets
BROAD POTENTIAL IN A PIPELINE OF UNDERSERVED MARKETS BENLYSTA Franchise Summary 20 U.S. SLE Groundwork in place to gain additional traction Positive leading indicators suggest continued progress Ex-U.S. Commercialization Vasculitis, Active Lupus Nephritis - potential indications beyond SLE
Slide 21: Manufacturing Supply to Meet Demand
Manufacturing Supply To Meet Demand HGS delivering worldwide supply / state-of-the-art capabilities Currently have at least a year's worth of inventory on hand 2 x 20K liters in-house manufacturing capacity for BENLYSTA Sufficient to produce worldwide supply for first 2-3 years of launch Lonza offer
Slide 22: HGS Pipeline: Future Growth Potential
Phase 3 trial in Asia initiated Q3 2011 Phase 3 trial of subcutaneous formulation initiated Q4 2011 Sales to Strategic National Stockpile under U.S. Government contract Initiation of Phase 3 trial planned 2H 2012 Formerly FP-1039. Rights acquired March 2011 from FivePrime Therapeutics. Phase 1b chem
Slide 23: Raxibacumab: Treatment for Inhalation Anthrax
RAXIBACUMAB Treatment for Inhalation Anthrax First 20,000 doses delivered H1 2009 to the U.S. Strategic National Stockpile; $163 million in revenue recognized through Q2 2009 45,000 more doses to be delivered over a three-year period; $142 million award; initiated 4Q09 $117 million in revenue recogn
Slide 24: Darapladib Phase 3 for Cardiovascular Disease
Discovered by GSK based on HGS technology 10% royalty on worldwide sales 20% co-promotion option in North America and Europe CV disease one of the largest markets in the pharmaceutical industry Darapladib Phase 3 for Cardiovascular Disease Lp-PLA2 inhibitor as a potential anti-atherosclerosis agent
Slide 25: Albiglutide Phase 3 for Type 2 Diabetes
Licensed to GSK Fees and milestone payments up to $183 million; up to $150 million still to be received1 Single-digit net royalties on worldwide sales Approximately 18.8 million diagnosed type 2 diabetes patients in the U.S.2 Albiglutide Phase 3 for Type 2 Diabetes Once-a-week GLP-1 agonist Eight Ph
Slide 26: HGS Oncology
HGS ONCOLOGY Mapatumumab (monoclonal antibody to the TRAIL-R1; HGS-ETR1) Targets TRAIL apoptosis pathway Phase 2 chemotherapy combo trial in hepatocellular carcinoma ongoing HGS1036 (first-in-class ligand trap targeting FGF pathway) Potential in various cancer indications Phase 1 data expected in 20
Slide 27: Strong Financial Position
Strong financial position Strengthened balance sheet with $429 million of proceeds from convertible note offering1 Expect cash and investments at year-end 2011: $875 - $885 million Expect R&D expense to total $195 - $205 million in 2011, and $150 - $180 million in 2012 Expect SG&A expense to total $
Slide 28: A Formula for Sustainable Growth
Potential Blockbuster Product Pipeline to Fuel Future Growth Manufacturing Excellence Commercial Readiness World-Class Partner Seasoned Leadership A Formula for Sustainable Growth Building Shareholder Value 28
Slide 29: Thank You
Thank You 29
Human Genome Sciences — JP Morgan Healthcare Conference 2012 on 6ix